newsfilter
← Latest News
PR Newswire·

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

  • Kazia Therapeutics CEO John Friend will attend the J.P. Morgan Healthcare Conference in San Francisco next week to meet with investors, analysts, & collaborators.
  • The company expects to release a clinical & biomarker update for its paxalisib Phase 1b trial in triple-negative breast cancer before the end of January 2026.
  • This update will include new data on circulating tumor cell reductions & cluster dynamics, supporting paxalisib's distinct mechanism beyond immunotherapy alone.
  • Kazia plans to provide the first update on its novel PD-L1 protein degrader program, which aims to address resistance & durability challenges in immune therapies.
  • Paxalisib is a brain-penetrant pan-PI3K/mTOR inhibitor currently being tested for brain cancer, advanced triple-negative breast cancer, & other solid tumors.
  • The company remains well-capitalized following recent financing to execute near-term catalysts & advance its oncology pipeline.